Effect of nebivolol and metoprolol treatments on serum asymmetric dimethlyarginine levels in hypertensive patients with type 2 diabetes mellitus.
Menevşe
Esma
E
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood / Q000187:drug effects; D001578:Benzopyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D015986:Confounding Factors, Epidemiologic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use*; D000068577:Nebivolol
D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D004983:Ethanolamines; C487735:dimethylarginine; D000068577:Nebivolol; D001120:Arginine; D008790:Metoprolol